Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The intent of this research protocol is to test the equivalency of two amyloid imaging drugs
(C11 Pittsburgh Compound B and F18 Flutemetamol). The investigators hypothesize that there
will be no significant difference in the distribution of the agents to areas of amyloid
deposition in the brain or to other normal brain structures. Recent data have shown
similarity in the distribution of the drugs in subjects with Alzheimer's disease (AD) or mild
cognitive impairment (MCI). No comparison data of the two PET drugs in normal subjects has
been published. It is important to understand differences in the images and biodistribution
from the two drugs in normal subjects as nonspecific accumulation of the drugs in brain
structures such as white matter appear to differ slightly and could affect image performance.